Trevi Therapeutics to Participate in Upcoming Events
Trevi Therapeutics, a clinical-stage biopharmaceutical company developing Haduvio™ for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC), announced senior management participation in key upcoming healthcare and biotech investor conferences. These e…